Evidence map›Paper›PMID 24942589›Full record

ArticleJournal of virology2014

All-in-one bacmids: an efficient reverse genetics strategy for influenza A virus vaccines.

Hongjun Chen, Matthew Angel, Weizhong Li, Courtney Finch, Ana Silvia Gonzalez, Troy Sutton, Jefferson Santos, Daniel R Perez

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Review
  3. Influenza Reverse Genetics-Historical Perspective.Cold Spring Harbor perspectives in medicine · 2021
    Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Hongjun ChenVirginia-Maryland Regional College of Veterinary Medicine, Department of Veterinary Medicine, University of Maryland, College Park, College Park, Maryland, USA.
Matthew AngelVirginia-Maryland Regional College of Veterinary Medicine, Department of Veterinary Medicine, University of Maryland, College Park, College Park, Maryland, USA.
Weizhong LiVirginia-Maryland Regional College of Veterinary Medicine, Department of Veterinary Medicine, University of Maryland, College Park, College Park, Maryland, USA.
Courtney FinchVirginia-Maryland Regional College of Veterinary Medicine, Department of Veterinary Medicine, University of Maryland, College Park, College Park, Maryland, USA.
Ana Silvia GonzalezVirginia-Maryland Regional College of Veterinary Medicine, Department of Veterinary Medicine, University of Maryland, College Park, College Park, Maryland, USA.
Troy SuttonVirginia-Maryland Regional College of Veterinary Medicine, Department of Veterinary Medicine, University of Maryland, College Park, College Park, Maryland, USA.
Jefferson SantosVirginia-Maryland Regional College of Veterinary Medicine, Department of Veterinary Medicine, University of Maryland, College Park, College Park, Maryland, USA.
Daniel R PerezVirginia-Maryland Regional College of Veterinary Medicine, Department of Veterinary Medicine, University of Maryland, College Park, College Park, Maryland, USA dperez1@umd.edu.ORCID http://orcid.org/0000-0002-6569-5689
University of Maryland, College Park · USVirginia–Maryland College of Veterinary Medicine · US

Funding

NIAID NIH HHS HHSN266200700010C
6 · The paper itself

Abstract

unlabelledVaccination is the first line of defense against influenza virus infection, yet influenza vaccine production methods are slow, antiquated, and expensive as a means to effectively reduce the virus burden during epidemic or pandemic periods. There is a great need for alternative influenza vaccines and vaccination methods with a global scale of impact. We demonstrate here a strategy to generate influenza A virus in vivo by using bacmid DNAs. Compared to the classical reverse genetics system, the "eight-in-one" bacmids (bcmd-RGFlu) showed higher efficiency of virus rescue in various cell types. Using a transfection-based inoculation (TBI) system, intranasal delivery to DBA/2J and BALB/c mice of bcmd-RGFlu plus 293T cells led to the generation of lethal PR8 virus in vivo. A prime-boost intranasal vaccination strategy using TBI in the context of a bcmd-RGFlu carrying a temperature-sensitive H1N1 virus resulted in protection of mice against lethal challenge with the PR8 strain. Taken together, these studies provide proof of principle to highlight the potential of vaccination against influenza virus by using in vivo reverse genetics. IMPORTANCE: Vaccination is the first line of defense against influenza virus infections. A major drawback in the preparation of influenza vaccines is that production relies on a heavily time-consuming process of growing the viruses in eggs. We propose a radical change in the way influenza vaccination is approached, in which a recombinant bacmid, a shuttle vector that can be propagated in both Escherichia coli and insect cells, carries an influenza virus infectious clone (bcmd-RGFlu). Using a surrogate cell system, we found that intranasal delivery of bcmd-RGFlu resulted in generation of influenza virus in mice. Furthermore, mice vaccinated with this system were protected against lethal influenza virus challenge. The study serves as a proof of principle of a potentially universal vaccine platform against influenza virus and other pathogens.

Indexed as

Genetic VectorsAdministration, IntranasalAnimalsDisease Models, AnimalInfluenza A virusInfluenza VaccinesMice, Inbred BALB CMice, Inbred DBAOrthomyxoviridae InfectionsReverse GeneticsInfluenza Vaccines

Identifiers

PMID24942589
PMCPMC4136356
OpenAlexW2164299458

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.